Concetta Altamura Selected Research

Myotonia

12/2021	Bioisosteric Modification of To042: Synthesis and Evaluation of Promising Use-Dependent Inhibitors of Voltage-Gated Sodium Channels.
1/2021	Buprenorphine may be effective for treatment of paramyotonia congenita.
1/2021	Ion Channel Gene Mutations Causing Skeletal Muscle Disorders: Pathomechanisms and Opportunities for Therapy.
1/2020	Skeletal muscle ClC-1 chloride channels in health and diseases.
1/2020	Safinamide's potential in treating nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo.
1/2019	Pharmacogenetics of myotonic hNav1.4 sodium channel variants situated near the fast inactivation gate.
1/2018	Effects of Benzothiazolamines on Voltage-Gated Sodium Channels.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Concetta Altamura Research Topics

Disease

7	Myotonia 12/2021 - 01/2018
5	Channelopathies 06/2022 - 10/2016
4	Myotonia Congenita (Thomsen Disease) 01/2018 - 10/2013
3	Neoplasms (Cancer) 06/2022 - 02/2021
3	Paralysis (Palsy) 01/2021 - 01/2021
2	Myotonic Disorders (Paramyotonia Congenita) 01/2021 - 01/2019
2	Rare Diseases (Rare Disease) 08/2020 - 01/2017
1	Multiple Myeloma 06/2022
1	Ovarian Neoplasms (Ovarian Cancer) 02/2021
1	Cardiac Arrhythmias (Arrythmia) 01/2021
1	Pain (Aches) 01/2021
1	Reperfusion Injury 01/2021
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2021
1	Fragile X Syndrome (Martin Bell Syndrome) 08/2020
1	Neurodevelopmental Disorders 08/2020
1	Epilepsy (Aura) 01/2020
1	Parkinson Disease (Parkinson's Disease) 01/2020
1	Potassium aggravated myotonia 01/2019
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2018
1	Stroke (Strokes) 01/2018
1	Ischemic Stroke 01/2018

Drug/Important Bio-Agent (IBA)

4	Ion Channels (Ion Channel)IBA 06/2022 - 01/2021
3	Pharmaceutical PreparationsIBA 02/2022 - 01/2019
3	Sodium Channel BlockersIBA 12/2021 - 01/2019
3	Mexiletine (Mexitil)FDA LinkGeneric 01/2021 - 01/2019
3	Chloride Channels (Chloride Channel)IBA 01/2020 - 10/2013
3	CLC-1 channelIBA 01/2018 - 09/2015
2	Sodium Channels (Sodium Channel)IBA 01/2021 - 01/2020
2	ChloridesIBA 01/2020 - 09/2015
2	Voltage-Gated Sodium ChannelsIBA 01/2020 - 01/2019
1	Tocainide (Tonocard)FDA Link 12/2021
1	PotassiumIBA 02/2021
1	Calcium Channels (Calcium Channel)IBA 02/2021
1	PlatinumIBA 02/2021
1	Epithelial Sodium ChannelsIBA 02/2021
1	Cardiotonic Agents (Cardiac Stimulants)IBA 01/2021
1	AntioxidantsIBA 01/2021
1	Buprenorphine (Subutex)FDA LinkGeneric 01/2021
1	Dichlorphenamide (Daranide)FDA Link 01/2021
1	SodiumIBA 01/2021
1	Serotonin (5 Hydroxytryptamine)IBA 08/2020
1	serotonin 7 receptorIBA 08/2020
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Levodopa (L Dopa)FDA LinkGeneric 01/2020
1	safinamideIBA 01/2020
1	Amino Acids FDA Link 01/2018
1	Neuroprotective AgentsIBA 01/2018
1	Riluzole FDA LinkGeneric 01/2018
1	lubeluzoleIBA 01/2018
1	Peptides (Polypeptides)IBA 01/2018
1	Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA 01/2017

Therapy/Procedure

4	Therapeutics 02/2021 - 10/2016
1	Drug Therapy (Chemotherapy) 02/2022
1	Precision Medicine 01/2021